* ECHOSENS *
2001 - IDF
Paris
www.echosens.com Discovery, Devices
Key words: Obesity, Hepatitis C, Hepatitis B, Fibroscan
Mission: to develop, manufacture and market new diagnostic devices in the field of hepatology (FibroScan being the first and only non-invasive device for diagnosis and monitoring of hepatic fibrosis)
Clients: Hospitals (through distributors and subsidiaries)
communication@echosens.com
Age: 8 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.-CEO: Guillaume (Richard) [born 1955, ex-Blatchford, Abbott, Mead Johnson]
Sc.Dir.-CSO: Sandrin (Laurent) [co-founder, ESCPI, Ph.D. physics, ex-LOA]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): OTC Asset Management, Cap Décisif | Turnover (M€) : 8.1 (2008), 7.2 (2007)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Liver
Position : Clinical
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .12 | Nomination : Richard Guillaume, new CEO, replacing Bertrand Fourquet | ORGN | [7 years] |
| 2007 .00 | Set-up of 3 subsidiaries in Spain, Germany and China, more than 330 FibroScan® installed worldwide | ORGC | [5 years] |
| 2004 .00 | Round-financing : undisclosed M€, by OTC and Cap Décisif, beginning of the commercialization of FibroScan with dedicated probe in France | RFIN | [2 years] |
| 2003 .11 | CE mark obtained for FibroScan | MKTG | [2 years] |
| 2001 .06 | Company founded by Sylvain Yon [born 1974], Bertrand Fourquet [Essec, as CEO], Laurent Sandrin, Jean-Michel Hasquenoph [ESTP], supported by ANVAR | ORGF | [0 year] | Actualisation / Updating: 29-Jun-2009 |
|
